Reference number(s)
3413-H

SPECIALTY QUANTITY LIMIT PROGRAM

BRUKINSA (zanubrutinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Brukinsa 80 mg capsules	120 per 30 days	Initial dose: 160 mg orally twice daily, or 320 mg orally once daily Dose adjustments are recommended for drug interactions with CYP3A inhibitors/inducers, and for adverse reactions.

III. REFERENCES

1. Brukinsa [package insert]. San Mateo, CA: BeiGene USA, Inc.; November 2019.